Aduro Biotech boss outlines immunotherapy clinical plans

With $373 million in the bank, and the possibility of development milestones on the way, Aduro Biotech has enough cash runway to take it through the end of 2020. Speaking at the recent Biotech Showcase meeting in San Francisco, company chairman, president and CEO Stephen Isaacs outlined to Informa Pharma Intelligence’s Mike Ward the company’s plans to develop its three core immunotherapy platforms. These comprise STING pathway modulators, B-select monoclonal antibodies and live, attenuated double-deleted Listeria monocytogenes, designed to stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies and or cutting edge immunotherapies.